Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 396

1.

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms.

Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK.

Blood Adv. 2019 May 14;3(9):1540-1545. doi: 10.1182/bloodadvances.2019000090.

2.

Andreas Vesalius and De Fabrica.

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2019 May;94(5):e67-e68. doi: 10.1016/j.mayocp.2019.03.018. No abstract available.

PMID:
31054619
3.

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.

Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G.

Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4.

PMID:
30926081
4.

Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.

El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, Amrein P, Stone RM, Temel JS, Greer JA.

Leukemia. 2019 Mar 28. doi: 10.1038/s41375-019-0449-1. [Epub ahead of print]

PMID:
30923318
5.

John Shaw Billings: Civil War Surgeon, Medical Librarian, Founder of Index Medicus, and First Director of the New York Public Library.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2019 Mar;94(3):e45-e46. doi: 10.1016/j.mayocp.2019.01.023. No abstract available.

PMID:
30832803
6.

Rethinking clinical trial endpoints in myelodysplastic syndromes.

Sekeres MA, Steensma DP.

Leukemia. 2019 Mar;33(3):570-575. doi: 10.1038/s41375-018-0367-7. Epub 2019 Jan 30. Review.

PMID:
30700839
7.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. [Epub ahead of print]

PMID:
30635634
8.

Georges de Bellio (1826-1894): Doctor, Friend, and Patron of the Impressionist Painters.

Dumitrascu DL, Kyle RA, Steensma DP.

Mayo Clin Proc. 2019 Jan;94(1):e7. doi: 10.1016/j.mayocp.2018.11.009. No abstract available.

PMID:
30611460
9.

Clinical consequences of clonal hematopoiesis of indeterminate potential.

Steensma DP.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):264-269. doi: 10.1182/asheducation-2018.1.264. Review.

PMID:
30504320
10.

Clinical consequences of clonal hematopoiesis of indeterminate potential.

Steensma DP.

Blood Adv. 2018 Nov 27;2(22):3404-3410. doi: 10.1182/bloodadvances.2018020222. Review.

11.

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials.

Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, Bowen D, de Witte T, Garcia-Manero G, Hellström-Lindberg E, Germing U, Stauder R, Malcovati L, Sekeres MA, Steensma DP, Gloaguen S.

Blood. 2019 Mar 7;133(10):1020-1030. doi: 10.1182/blood-2018-06-857102. Epub 2018 Nov 7. Review.

PMID:
30404811
12.

Herman Boerhaave - Master Clinician and Humanist.

Kyle RA, Steensma DP.

Mayo Clin Proc. 2018 Nov;93(11):e119-e120. doi: 10.1016/j.mayocp.2018.09.014. No abstract available.

PMID:
30392557
13.

Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.

Steensma DP, Brunner AM, DeZern AE, Garcia-Manero G, Komrokji RS, Odenike OS, Roboz GJ, Savona MR, Stone RM, Sekeres MA.

Cancer. 2018 Dec 15;124(24):4601-4609. doi: 10.1002/cncr.31769. Epub 2018 Oct 5.

PMID:
30289970
14.

An RNA bestiary in splicing-mutant MDS.

Steensma DP.

Blood. 2018 Sep 20;132(12):1217-1219. doi: 10.1182/blood-2018-07-859942. No abstract available.

PMID:
30237252
15.

Werner Forssmann: A Pioneer of Interventional Cardiology and Auto-Experimentation.

Afshar A, Steensma DP, Kyle RA.

Mayo Clin Proc. 2018 Sep;93(9):e97-e98. doi: 10.1016/j.mayocp.2017.08.026. No abstract available.

PMID:
30193685
16.

How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes.

Steensma DP.

Blood. 2018 Oct 18;132(16):1657-1663. doi: 10.1182/blood-2018-06-860882. Epub 2018 Sep 5. Review. Erratum in: Blood. 2018 Nov 29;132(22):2419.

PMID:
30185432
17.

Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia.

El-Jawahri A, Nelson-Lowe M, VanDusen H, Traeger L, Abel GA, Greer JA, Fathi A, Steensma DP, LeBlanc TW, Li Z, DeAngelo D, Wadleigh M, Hobbs G, Foster J, Brunner A, Amrein P, Stone RM, Temel JS.

Oncologist. 2019 Feb;24(2):247-254. doi: 10.1634/theoncologist.2018-0317. Epub 2018 Aug 23.

PMID:
30139841
18.

Clinical Implications of Clonal Hematopoiesis.

Steensma DP.

Mayo Clin Proc. 2018 Aug;93(8):1122-1130. doi: 10.1016/j.mayocp.2018.04.002. Epub 2018 Jul 4. Review.

PMID:
30078412
19.

Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R.

Benton CB, Khan M, Sallman D, Nazha A, Nogueras González GM, Piao J, Ning J, Aung F, Al Ali N, Jabbour E, Kadia TM, Borthakur G, Ravandi F, Pierce S, Steensma D, DeZern A, Roboz G, Sekeres M, Andreeff M, Kantarjian H, Komrokji RS, Garcia-Manero G.

Am J Hematol. 2018 Oct;93(10):1245-1253. doi: 10.1002/ajh.25234. Epub 2018 Sep 26.

PMID:
30051599
20.

Uncoupling of CD71 shedding with mitochondrial clearance in reticulocytes in a subset of myelodysplastic syndromes.

Zhang Q, Steensma DP, Yang J, Dong T, Wu MX.

Leukemia. 2019 Jan;33(1):217-229. doi: 10.1038/s41375-018-0204-z. Epub 2018 Jul 26.

PMID:
30050123

Supplemental Content

Loading ...
Support Center